Role of platinum agents in the management of advanced pancreatic cancer

Bibliography

• JEMAL A, SIEGEL R, WARD E, MURRAY T, XU J, THUN MJ: Cancer statistics, 2007. CA Cancer J. Clin. (2007) 57(1):43-66.
   PubMed Web of Science ®Google Scholar
• BURRIS HA III, MOORE MJ, ANDERSEN J et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. (1997) 15(6):2403-2413.
   PubMed Web of Science ®Google Scholar
• MOORE MJ, GOLDSTEIN D, HAMM J et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National cancer institute of Canada clinical trials group. J. Clin. Oncol. (2007) 25(15):1960-1966.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM D, CHAU I, STOCKEN D et al.: Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM–CAP) in patients with advanced pancreatic cancer. Eur. J. Cancer Suppl. (2005) 4:Abstr. PS11.
   Google Scholar
• WILS JA, KOK T, WAGENER DJ, SELLESLAGS J, DUEZ N: Activity of cisplatin in adenocarcinoma of the pancreas. Eur. J. Cancer (1993) 29A(2):203-204.
   PubMed Web of Science ®Google Scholar
• CARTER SK, COMIS RL: The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat. Rev. (1975) 2(3):193-214.
   PubMed Web of Science ®Google Scholar
• CULLINAN SA, MOERTEL CG, FLEMING TR et al.: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA (1985) 253(14):2061-2067.
   PubMed Web of Science ®Google Scholar
• ROUGIER P, ZARBA JJ, DUCREUX M et al.: Phase II study of cisplatin and 120-h continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann. Oncol. (1993) 4(4):333-336.
   PubMed Web of Science ®Google Scholar
• DUCREUX M, ROUGIER P, PIGNON JP et al.: A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann. Oncol. (2002) 13(8):1185-1191.
   PubMed Web of Science ®Google Scholar
• BERGMAN AM, RUIZ VAN HAPEREN VW, VEERMAN G, KUIPER CM, PETERS GJ: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin. Cancer Res. (1996) 2(3):521-530.
   PubMed Web of Science ®Google Scholar
• VAN MOORSEL CJ, PINEDO HM, VEERMAN G et al.: Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br. J. Cancer (1999) 80(7):981-990.
   PubMed Web of Science ®Google Scholar
• HEINEMANN V, WILKE H, MERGENTHALER HG et al.: Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann. Oncol. (2000) 11(11):1399-1403.
   PubMed Web of Science ®Google Scholar
• HEINEMANN V, QUIETZSCH D, GIESELER F et al.: Randomized Phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. (2006) 24(24):3946-3952.
   PubMed Web of Science ®Google Scholar
• COLUCCI G, GIULIANI F, GEBBIA V et al.: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized Phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer (2002) 94(4):902-910.
   PubMed Web of Science ®Google Scholar
• XIROS N, PAPACOSTAS P, ECONOMOPOULOS T et al.: Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a Phase II multicenter study by the Hellenic cooperative oncology group. Ann. Oncol. (2005) 16(5):773-779.
   PubMed Web of Science ®Google Scholar
• DUCREUX M, VAN CUTSEM E, VAN LAETHEM JL et al.: A randomised Phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur. J. Cancer (2005) 41(3):398-403.
   PubMed Web of Science ®Google Scholar
• FAIVRE S, RAYMOND E, WOYNAROWSKI JM, CVITKOVIC E: Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother. Pharmacol. (1999) 44(2):117-123.
   PubMed Web of Science ®Google Scholar
• AIROLDI M, CATTEL L, PASSERA R, PEDANI F, MILLA P, ZANON C: Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data. Pancreas (2006) 32(1):44-50.
   PubMed Web of Science ®Google Scholar
• LOUVET C, ANDRE T, LLEDO G et al.: Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter Phase II study. J. Clin. Oncol. (2002) 20(6):1512-1518.
   PubMed Web of Science ®Google Scholar
• LOUVET C, LABIANCA R, HAMMEL P et al.: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III trial. J. Clin. Oncol. (2005) 23(15):3509-3516.
   PubMed Web of Science ®Google Scholar
• POPLIN E, LEVY DE, BERLIN J et al.: Phase III trial of gemcitabine (30-min infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). Proc. Am. Soc. Clin. Oncol. (2006) 24:Abstr. 4004.
   Google Scholar
• YIP D, KARAPETIS C, STRICKLAND A, STEER CB, GOLDSTEIN D: Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst. Rev. (2006) 3:CD002093 (Online).
   Google Scholar
• LOUVET CHA, LABIANCA R, HEINEMANN V: Increased survival using platinum analog combined with gemcitabine as compared to gemcitabine single agent in advanced pancreatic cancer (APC): pooled analysis of two randomised trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Proc. Am. Soc. Clin. Oncol. (2006) 24:Abstr. 4003.
   PubMedGoogle Scholar
• HEINEMANN V, HINKE A, BOECK S, LOUVET C: Benefit from gemcitabine-based combination treatment in advanced pancreatic cancer: a meta-analysis of randomized trials. Proc. GI Am. Soc. Clin. Oncol. (2007):Abstr. 129.
   Google Scholar
• ITAKURA J, ISHIWATA T, SHEN B, KORNMANN M, KORC M: Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int. J. cancer (2000) 85(1):27-34.
   PubMed Web of Science ®Google Scholar
• BRUNS CJ, SOLORZANO CC, HARBISON MT et al.: Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. (2000) 60(11):2926-2935.
   PubMed Web of Science ®Google Scholar
• MOORE MJ, GOLDSTEIN D, HAMM J et al.: Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A Phase III trial of the national cancer institute of canada clinical trials group [NCIC-CTG]. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstr. 1.
   Google Scholar
• KINDLER HL, NIEDZWIECKI D, HOLLIS D et al.: A double-blind, placebo-controlled, randomized Phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of cancer and leukemia group B (CALGB) 80303. Proc. GI Am. Soc. Clin. Oncol. (2007):Abstr. 108.
   Google Scholar
• KULLMANN F, HOUERBACH S, DOLLINGER M et al.: Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in 1st line metastatic pancreatic cancer. First results from a multicenter Phase II study. Proc. GI Am. Soc. Clin. Oncol. (2007):Abstr. 128.
   Google Scholar
• KIM GP, ALBERTS SR, OBERG AL et al.: Phase II trial of bevacizumab, gemcitabine, and oxaliplatin in patients with metastatic pancreatic adenocarcinoma. Proc. GI Am. Soc. Clin. Oncol. (2007):Abstr. 169.
   Google Scholar
• GHOSN M, FARHAT F, KATTAN J et al.: FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer. Am. J. Clin. Oncol. (2007) 30(1):15-20.
   PubMed Web of Science ®Google Scholar
• YCHOU M, DESSEIGNE M, GUIMBAUD R et al.: Randomized Phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial. Proc. Am. Soc. Clin. Oncol. (2007) 25:(Abstract 4516).
   PubMedGoogle Scholar
• HEINEMANN V, HOEHLER T, SEIPELT G et al.: Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx): a randomized Phase II trial in advanced pancreatic cancer. Proc. GI Am. Soc. Clin. Oncol. (2005) 23:(Abstract 4030).
   Google Scholar
• HERRMANN R, BODOKY G, RUHSTALLER T et al.: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, Phase III trial of the Swiss group for clinical cancer research and the central European cooperative oncology group. J. Clin. Oncol. (2007) 25(16):2212-2217.
   PubMed Web of Science ®Google Scholar
• BERLIN JD, CATALANO P, THOMAS JP, KUGLER JW, HALLER DG, BENSON AB III: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern cooperative oncology group trial E2297. J. Clin. Oncol. (2002) 20(15):3270-3275.
   PubMed Web of Science ®Google Scholar
• ROCHA LIMA CM, GREEN MR, ROTCHE R et al.: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. (2004) 22(18):3776-3783.
   PubMed Web of Science ®Google Scholar
• ABOU-ALFA GK, LETOURNEAU R, HARKER G et al.: Randomized Phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J. Clin. Oncol. (2006) 24(27):4441-4447.
   PubMed Web of Science ®Google Scholar
• OETTLE H, RICHARDS D, RAMANATHAN RK et al.: A Phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann. Oncol. (2005) 16(10):1639-1645.
   PubMed Web of Science ®Google Scholar
• VAN CUTSEM E, VAN DE VELDE H, KARASEK P et al.: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. (2004) 22(8):1430-1438.
   PubMed Web of Science ®Google Scholar
• BRAMHALL SR, SCHULZ J, NEMUNAITIS J, BROWN PD, BAILLET M, BUCKELS JA: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer (2002) 87(2):161-167.
   PubMed Web of Science ®Google Scholar